Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to α-interferon in chronic myelogenous leukemia

Tokiko Inoue, Arinobu Tojo, Daisuke Tsuchimoto, Shin Ichiro Okamoto, Hiromi Ogura, Kenzaburo Tani, Keiya Ozawa, Masabumi Shibuya, Shigetaka Asano

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Twenty six patients with Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia (CML) treated with IFN-α were classified on the basis of the fusion pattern of BCR/ABL chimeric mRNA determined by a reverse-transcriptase-polymerase chain reaction (RT-PCR) method. The relationship between the fusion pattern of BCR/ABL mRNA and the clinical outcome was also analysed. Twelve patients showed M-bcr exon 3/ABL exon 2 (B3/A2) chimeric mRNA and nine had M-bcr exon 2/ABL exon 2 (B2/A2) mRNA. Eleven of the 12 patients with B3/A2 achieved complete hematological response with IFN-α therapy, as did three of the nine patients with B2/A2. The mean duration to blastic crisis was significantly longer in the B3/A2 patients (mean 52.4 months) than in the B2/A2 patients (mean 26.2 months) (p<0.01). These results suggest that the fusion pattern of BCR/ABL mRNA may affect the therapeutic response to IFN-α and clinical outcome in CML patients.

Original languageEnglish
Pages (from-to)948-951
Number of pages4
JournalLeukemia
Volume6
Issue number9
Publication statusPublished - Jan 1 1992
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferons
Exons
Messenger RNA
Philadelphia Chromosome
Reverse Transcriptase Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to α-interferon in chronic myelogenous leukemia. / Inoue, Tokiko; Tojo, Arinobu; Tsuchimoto, Daisuke; Okamoto, Shin Ichiro; Ogura, Hiromi; Tani, Kenzaburo; Ozawa, Keiya; Shibuya, Masabumi; Asano, Shigetaka.

In: Leukemia, Vol. 6, No. 9, 01.01.1992, p. 948-951.

Research output: Contribution to journalArticle

Inoue, T, Tojo, A, Tsuchimoto, D, Okamoto, SI, Ogura, H, Tani, K, Ozawa, K, Shibuya, M & Asano, S 1992, 'Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to α-interferon in chronic myelogenous leukemia', Leukemia, vol. 6, no. 9, pp. 948-951.
Inoue, Tokiko ; Tojo, Arinobu ; Tsuchimoto, Daisuke ; Okamoto, Shin Ichiro ; Ogura, Hiromi ; Tani, Kenzaburo ; Ozawa, Keiya ; Shibuya, Masabumi ; Asano, Shigetaka. / Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to α-interferon in chronic myelogenous leukemia. In: Leukemia. 1992 ; Vol. 6, No. 9. pp. 948-951.
@article{b07315001da843c4807e023fc09f3ed0,
title = "Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to α-interferon in chronic myelogenous leukemia",
abstract = "Twenty six patients with Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia (CML) treated with IFN-α were classified on the basis of the fusion pattern of BCR/ABL chimeric mRNA determined by a reverse-transcriptase-polymerase chain reaction (RT-PCR) method. The relationship between the fusion pattern of BCR/ABL mRNA and the clinical outcome was also analysed. Twelve patients showed M-bcr exon 3/ABL exon 2 (B3/A2) chimeric mRNA and nine had M-bcr exon 2/ABL exon 2 (B2/A2) mRNA. Eleven of the 12 patients with B3/A2 achieved complete hematological response with IFN-α therapy, as did three of the nine patients with B2/A2. The mean duration to blastic crisis was significantly longer in the B3/A2 patients (mean 52.4 months) than in the B2/A2 patients (mean 26.2 months) (p<0.01). These results suggest that the fusion pattern of BCR/ABL mRNA may affect the therapeutic response to IFN-α and clinical outcome in CML patients.",
author = "Tokiko Inoue and Arinobu Tojo and Daisuke Tsuchimoto and Okamoto, {Shin Ichiro} and Hiromi Ogura and Kenzaburo Tani and Keiya Ozawa and Masabumi Shibuya and Shigetaka Asano",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "948--951",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to α-interferon in chronic myelogenous leukemia

AU - Inoue, Tokiko

AU - Tojo, Arinobu

AU - Tsuchimoto, Daisuke

AU - Okamoto, Shin Ichiro

AU - Ogura, Hiromi

AU - Tani, Kenzaburo

AU - Ozawa, Keiya

AU - Shibuya, Masabumi

AU - Asano, Shigetaka

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Twenty six patients with Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia (CML) treated with IFN-α were classified on the basis of the fusion pattern of BCR/ABL chimeric mRNA determined by a reverse-transcriptase-polymerase chain reaction (RT-PCR) method. The relationship between the fusion pattern of BCR/ABL mRNA and the clinical outcome was also analysed. Twelve patients showed M-bcr exon 3/ABL exon 2 (B3/A2) chimeric mRNA and nine had M-bcr exon 2/ABL exon 2 (B2/A2) mRNA. Eleven of the 12 patients with B3/A2 achieved complete hematological response with IFN-α therapy, as did three of the nine patients with B2/A2. The mean duration to blastic crisis was significantly longer in the B3/A2 patients (mean 52.4 months) than in the B2/A2 patients (mean 26.2 months) (p<0.01). These results suggest that the fusion pattern of BCR/ABL mRNA may affect the therapeutic response to IFN-α and clinical outcome in CML patients.

AB - Twenty six patients with Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia (CML) treated with IFN-α were classified on the basis of the fusion pattern of BCR/ABL chimeric mRNA determined by a reverse-transcriptase-polymerase chain reaction (RT-PCR) method. The relationship between the fusion pattern of BCR/ABL mRNA and the clinical outcome was also analysed. Twelve patients showed M-bcr exon 3/ABL exon 2 (B3/A2) chimeric mRNA and nine had M-bcr exon 2/ABL exon 2 (B2/A2) mRNA. Eleven of the 12 patients with B3/A2 achieved complete hematological response with IFN-α therapy, as did three of the nine patients with B2/A2. The mean duration to blastic crisis was significantly longer in the B3/A2 patients (mean 52.4 months) than in the B2/A2 patients (mean 26.2 months) (p<0.01). These results suggest that the fusion pattern of BCR/ABL mRNA may affect the therapeutic response to IFN-α and clinical outcome in CML patients.

UR - http://www.scopus.com/inward/record.url?scp=0026688329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026688329&partnerID=8YFLogxK

M3 - Article

C2 - 1518306

AN - SCOPUS:0026688329

VL - 6

SP - 948

EP - 951

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -